Considering the central role of BCR-signalling on CLL pathogenesis, the capacity to inhibit leukemic cell activation adds an attractive immunomodulatory effect to IVIg preparations for CLL patients. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.